Non-autoreactive Chronic Spontaneous Urticaria | Profiling Urticaria for the Identification of Subtypes
Non-autoreactive Chronic Spontaneous Urticaria research study
What is the primary objective of this study?
The primary purpose of this study is to identify and characterize novel diagnostic markers for autoimmune urticaria, a subset of chronic spontaneous urticaria. Additional aims: include the comparison of the clinical profiles of autoreactive, autoimmune and non autoreactive / autoimmune urticaria and the quality of life impairment in these subsets of chronic spontaneous urticaria.
Who is eligible to participate?
Inclusion Criteria: - chronic spontaneous urticaria - disease duration > 6 weeks - signed and dated informed consent - age 18 years or older - Non sedating antihistamines may be used on an \"on demand\" basis throughout the study, in case of high urticaria activity [>50 wheals, and intense pruritus: urticaria activity score (UAS) of 6] or in case of an emergency. Patients may take either cetirizine 10 mg up to a maximum of 4 tablets per 24 hours or fexofenadine 180 mg up to a maximum of 4 tablets per 24 hours. The use of antihistamines and the reason has to be documented by the patient in the patient diary. Patients should avoid the use of antihistamines during the study and especially during the three days prior to skin testing - for female with childbearing potential: female will have to use a safe method of contraception to prevent pregnancy and will have to agree to continue this method of contraception during the whole study. Exclusion Criteria: - intake of immunosuppressives 3 month before Screening Visit and during the course of the study. Immunosuppressives including ciclosporin, methotrexate, mycophenolate, azathioprine and cyclophosphamide need to be stopped at least 3 month before Screening Visit - intake of corticosteroids (e.g. oral, injection) 1 month before Screening Visit and during the course of the study. Corticosteroids need to be stopped at least 1 month before the Screening Visit. - Previous or present treatment with anti-IgE-antibodies including omalizumab (Xolair) - age below 18 years - use of tricyclic antidepressants (e.g. amitriptyline), doxepin, leukotriene antagonists (e.g. montelukast, trade name: singulair), H2 antihistamines (e.g. cimetidine, famotidine, ranitidine), sulphasalazine, dapsone, tranexamic acid, warfarin, heparin during the last 4 weeks before the Screening Visit and during the course of the study. - pregnancy, lactation or planned pregnancy during the study - mentally incapacitated subjects - patients protected by the law (adults under guardianship, or hospitalized in a public or private institution for a reason other than the study, or incarcerated) - patients suffering from urticaria vasculitis
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Non-autoreactive Chronic Spontaneous Urticaria
Autoimmune Chronic Spontaneous Urticaria
Autoreactive, Non-autoimmune Chronic Spontaneous Urticaria
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
autoimmune chronic spontaneous urticariaPatients with chronic spontaneous urticaria with a positive ASST, who also test positive in a cell activating assay (BHRA OR CD 63 activation of healthy donor basophils) and who exhibit anti-FcεRI and/or anti-IgE autoantibodies (=autoimmune chronic spontaneous urticaria).
autoreactive, non-autoimmune chronic spontaneous urticariaPatients with chronic spontaneous urticaria with a positive ASST, who test negative in cell activation assay or who do not exhibit anti-FcεRI or anti-IgE autoantibodies (=autoreactive, non-autoimmune chronic spontaneous urticaria)
non-autoreactive chronic spontaneous urticariaPatients with chronic spontaneous urticaria and a negative ASST (= non-autoreactive chronic spontaneous urticaria)
Start Date: July 2011
Completed Date: June 2015
Primary Outcome: Results of the ASST
Secondary Outcome: Results of Urticaria activity score (UAS7)
Study sponsors, principal investigator, and references
Principal Investigator: Marcus Maurer, Prof. Dr. med.
Lead Sponsor: Marcus Maurer